Go back to Resource Center
The risk of secondary malignancies following purine analog therapy of chronic lymphocytic leukemia (CLL) and hairy cell leukemia (HCL).
1997
Journal Article
Authors:
D, B.J.Vena
Secondary:
Proc ASCO.
Pagination:
52
